Drugmaker Actavis said on Tuesday that it will buy Forest Laboratories for approximately $25 billion. The deal stands to give Actavis a broader portfolio of pharmaceuticals, which would enable the combined company to sell more products to doctors and hospitals, according to James Molloy, Managing Director at Janney Montgomery Scott. Molloy explains why he believes the deal is a smart one for Actavis and weighs in on speculation over whether or not Forest Labs is likely to receive a better offer.

Brittany joined TheStreet.com TV in November 2006 after completing a degree in Journalism and Media Studies at Rutgers College. Previously, Brittany interned at the local ABC affiliate in New York City WABC-TV 7 where she helped research and produce On Your Side, a popular consumer advocacy segment.

More from Video

Rent the Runway co-founder Chats with Cramer on Equal Pay and a Good Pair Jeans

Rent the Runway co-founder Chats with Cramer on Equal Pay and a Good Pair Jeans

Video: Jim Cramer Reacts to Tiffany's Better Than Expected Earnings

Video: Jim Cramer Reacts to Tiffany's Better Than Expected Earnings

Jim Cramer: Union Pacific Is Positive on NAFTA Talks

Jim Cramer: Union Pacific Is Positive on NAFTA Talks

Jim Cramer: I Remain Constructive on Micron Shares

Jim Cramer: I Remain Constructive on Micron Shares

Video: Jim Cramer on Why the Market Opened Lower on Wednesday

Video: Jim Cramer on Why the Market Opened Lower on Wednesday